Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more
Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more
Whether you’re producing viral vectors at clinical and commercial scales, manufacturing recombinant proteins and monoclonal antibodies, performing knock-out studies with siRNA, or editing genes using CRISPR, we have the nucleic acid delivery system you need.
Mirus was founded in 1995 to address the limitations and risks of viral gene transfer. We developed the first pDNA transfection method that combined high efficiency with low cellular toxicity, and since that time, we’ve focused on applying intentional design to nucleic acid delivery systems.
TransIT-VirusGEN® Transfection Reagent is designed to enhance delivery of packaging and transfer plasmids to adherent and suspension HEK 293 cell types to increase recombinant adeno-associated virus (AAV) and lentivirus production.
In this podcast, listen to the first-hand account of how researchers from St. Jude overcame the challenges with viral vector optimization to produce ground-breaking gene therapy for hemophilia with the hope to start treating patients on a large-scale in 2023.
